The EPO granted patent EP3836801A1 to Société des Produits Nestlé S.A. covering peanut oral immunotherapy compositions and methods for maintaining desensitization in patients with peanut allergies. The patent application EP3836801 was published in A1 kind (with search report) on March 25, 2026, and is classified under A61K 39/35 (allergen products), A23L 25/00 (food compositions), and G01N 33/543 (immunoassay methods). The designated contracting states cover all major European Patent Convention members.

Pharmaceutical companies and food manufacturers developing allergen immunotherapy products should review the patent claims to assess potential freedom-to-operate implications. Healthcare providers offering or planning oral immunotherapy programs should be aware of proprietary treatment approaches. No immediate compliance action is required as patents grant exclusionary rights rather than impose regulatory obligations.